Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for determining the effectiveness of a treatment for preeclampsia

A pre-eclampsia, effective technology, applied in the direction of material inspection products, measuring devices, instruments, etc., can solve the problems of difficult resuscitation, neuromuscular block, mother and fetus complications, etc.

Inactive Publication Date: 2009-04-22
DIAGNOSTIC TECH
View PDF4 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In many of these treatments, side effects such as cerebral hemorrhage, neuromuscular blockade, and difficulties with resuscitation can occur and cause complications for the mother and fetus

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for determining the effectiveness of a treatment for preeclampsia
  • Method for determining the effectiveness of a treatment for preeclampsia
  • Method for determining the effectiveness of a treatment for preeclampsia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0106] Example 1: Evaluation of the effectiveness of treatment by low-dose aspirin

[0107] If drug therapy is applied for the periods specified above, it is expected that a woman's PP13 levels will return to the 2nd and 3rd and even 4th quartiles, corresponding to her reduced likelihood of developing preeclampsia. In the example described in Table 2, women at increased risk of developing preeclampsia were treated with aspirin 100 mg / kg (low dose aspirin) orally for 2 or 3 weeks starting from the 8th week of pregnancy. It suggests that giving aspirin early enough reduces the risk of subsequent development of preeclampsia. Therefore, women receiving treatment can expect to reduce their risk of developing preeclampsia and improve their outcomes.

[0108] As shown in Table 2, in the trial, 150 women were tested as being at high risk at week 8, 50 were untreated, 50 were treated with aspirin for two weeks and 50 were treated with aspirin for three weeks. The results showed that ...

Embodiment 2

[0113] Example 2: Evaluation of the effectiveness of treatment by anticoagulant drugs

[0114] Women considered to be at increased risk were given daily anticoagulant therapy (low molecular weight heparin, aprotinin, or other) from the eighth week of pregnancy for 2 weeks. It was found that their PP13 MoM increased to 0.48 (gestational weeks 11-15) (P<0.05) and 0.73 (gestational weeks 16-20), respectively, and the latter was practically indistinguishable from normal levels (1±0.29, median normal MoM± 95% confidence interval). PP13 MoM was not affected in normal risk women. The corresponding outcomes for treated women were: Over the entire cycle, all 5 women at increased risk developed severe preeclampsia in the no treatment group, whereas only one developed severe preeclampsia and one mild preeclampsia in the treatment group and one unaffected.

Embodiment 3

[0115] Example 3: Evaluation of Drug Benefits Using Placental Extracts

[0116] An alternate method of assessing drug benefit is through the use of placental villi (cells or explants) obtained from women at 9-10 weeks of gestation by chorionic villus sampling. Placental cells / explants were cultured for 48 hours and PP13 was assayed in the culture medium by ELISA (in the same manner as described in Figure 1). The results are shown in Table 3 below.

[0117] Table 3 shows 3 cases of preeclampsia (cases #3, 4, 5) in 6% oxygen (normoxic) compared to 14,100 and 15,700 in normal women (cases #1 and 2) In comparison, the amount released was significantly lower (3,010, 3,500 and 6,300). After 48 hours of incubation with the antioxidant vitamin C (which has shown promise in treating high-risk women), PP13 release levels returned to almost normal levels in all three high-risk women, reaching 12,030, 9,230 and 15,790 (ie 3-4 times higher). At 20% oxygen (hyperoxia), PP13 release incr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A method for determining the effectiveness of a treatment for preeclampsia of a pregnant woman at risk for preeclampsia, the method comprising: (a) determining a first concentration of placental protein 13 (PP13) in a bodily substance of the woman obtained prior to the treatment; (b) determining a second concentration of PP13 in a bodily substance of the woman obtained after initiation of the treatment; and (c) comparing the first and second concentrations to a corresponding normal level of PP13 and, based on the comparison, determining the effectiveness of the treatment. Diagnostic kits for practicing the method are also disclosed.

Description

field of invention [0001] The present invention relates to a method for customizing a drug to treat or prevent preeclampsia and monitoring its effectiveness. Background of the invention [0002] A pregnancy disorder known as preeclampsia (PE) is a pregnancy complication that occurs in 5-7% of all pregnancies and is the second most common cause of maternal death during pregnancy (18% of maternal deaths in the U.S. rate is associated with pregnancy). Preeclampsia was defined as a new episode of hypertension after 20 weeks' gestation in a previously normotensive woman. The World Congress on Hypertension in Pregnancy has provided the following definition for the diagnosis of preeclampsia: New episodes of hypertension developing after 20 weeks of gestation, separated by 4-6 hours (in Two measurements ≥ 90 / 140 mm Hg (systolic / diastolic, at least once) 4-72 hours apart in some cases) combined with apparent or measured protein corresponding to 300 mg / DL in urine collected within 2...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/68
CPCG01N2333/471G01N2800/368G01N2800/52G01N33/689
Inventor H·梅里
Owner DIAGNOSTIC TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com